CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for TuHURA Biosciences Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

TuHURA Biosciences Inc
10500 University Center Dr., Suite 110
Phone: (813) 875-6600p:813 875-6600 TAMPA, FL  33612  United States Ticker: HURAHURA
Business Summary
TuHURA Biosciences, Inc. is a Phase III registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The Company’s personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase III registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first line treatment for advanced Merkel cell carcinoma. It is leveraging its Delta receptor technology to develop tumor microenvironment modulators in the form of first-in-class bi-specific antibody-peptide conjugates (APCs) and antibody-drug conjugates (ADCs) targeting Myeloid Derived Suppressor Cells (MDSCs). In addition to its innate immune agonist candidates, the Company plans to advance its VISTA-inhibiting antibody into a phase II trial in combination with a menin inhibitor in NPM1 mutated relapsed or refractory AML.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202412/31/2024YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Robert E.Hoffman 60 10/18/2024 4/11/2018
Chief Executive Officer, Director JamesBianco 68 10/18/2024 10/18/2024
Chief Financial Officer DanielDearborn 57 10/18/2024 10/18/2024
6 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Adgero Biopharmaceuticals Holdings Inc 4365 US Highway 1 Ste 211 PRINCETON NJ United States

Business Names
Business Name
0959454 B.C. Ltd.
0959456 B.C. Ltd.
Adgero Biopharmaceuticals Holdings, Inc.
9 additional Business Names available in full report.

General Information
Number of Employees: 19 (As of 12/31/2024)
Outstanding Shares: 43,680,397 (As of 3/31/2025)
Shareholders: 606
Stock Exchange: NASD
Federal Tax Id: 990360497
Fax Number: (604) 202-1384


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, May 12, 2025